HRP20201991T1 - Sustav za isporuku tekućeg polimera za produženu administraciju lijekova - Google Patents

Sustav za isporuku tekućeg polimera za produženu administraciju lijekova Download PDF

Info

Publication number
HRP20201991T1
HRP20201991T1 HRP20201991TT HRP20201991T HRP20201991T1 HR P20201991 T1 HRP20201991 T1 HR P20201991T1 HR P20201991T T HRP20201991T T HR P20201991TT HR P20201991 T HRP20201991 T HR P20201991T HR P20201991 T1 HRP20201991 T1 HR P20201991T1
Authority
HR
Croatia
Prior art keywords
liquid polymer
polymer composition
composition according
injection
pharmaceutical agent
Prior art date
Application number
HRP20201991TT
Other languages
English (en)
Croatian (hr)
Inventor
John Milton Downing
Vipin SAXENA
John Middleton
Original Assignee
Tolmar International Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tolmar International Limited filed Critical Tolmar International Limited
Publication of HRP20201991T1 publication Critical patent/HRP20201991T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/09Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/29Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593Polyesters, e.g. PLGA or polylactide-co-glycolide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
HRP20201991TT 2015-08-03 2016-08-03 Sustav za isporuku tekućeg polimera za produženu administraciju lijekova HRP20201991T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562200198P 2015-08-03 2015-08-03
US201662275407P 2016-01-06 2016-01-06
EP16751437.1A EP3331495B1 (en) 2015-08-03 2016-08-03 Liquid polymer delivery system for extended administration of drugs
PCT/US2016/045334 WO2017024027A1 (en) 2015-08-03 2016-08-03 Liquid polymer delivery system for extended administration of drugs

Publications (1)

Publication Number Publication Date
HRP20201991T1 true HRP20201991T1 (hr) 2021-02-05

Family

ID=56684769

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20201991TT HRP20201991T1 (hr) 2015-08-03 2016-08-03 Sustav za isporuku tekućeg polimera za produženu administraciju lijekova

Country Status (19)

Country Link
US (3) US10786515B2 (https=)
EP (2) EP3804698B1 (https=)
JP (1) JP6949820B2 (https=)
KR (1) KR102696721B1 (https=)
CN (1) CN107920988B (https=)
AU (1) AU2016302252B2 (https=)
BR (1) BR112018002414B1 (https=)
CA (1) CA2994704A1 (https=)
DK (1) DK3331495T3 (https=)
EA (1) EA036951B1 (https=)
ES (2) ES2836805T3 (https=)
HR (1) HRP20201991T1 (https=)
HU (1) HUE052832T2 (https=)
IL (1) IL257221B (https=)
MX (1) MX378264B (https=)
PT (1) PT3331495T (https=)
TW (1) TWI718168B (https=)
WO (1) WO2017024027A1 (https=)
ZA (1) ZA201800591B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008009125A (es) 2006-01-18 2008-10-23 Qps Llc Composiciones farmaceuticas con estabilidad mejorada.
US10786515B2 (en) 2015-08-03 2020-09-29 Tolmar International Limited Liquid polymer delivery system for extended administration of drugs
WO2019232285A1 (en) 2018-05-30 2019-12-05 Purdue Research Foundation Targeting anabolic drugs for accelerated fracture repair
KR102051808B1 (ko) 2018-07-23 2019-12-04 주식회사 종근당 테스토스테론 운데카노에이트를 포함하는 안정한 약제학적 조성물
UY38386A (es) 2018-09-25 2020-04-30 Tolmar Int Ltd Sistema de suministro de polímero líquido para la administración prolongada de fármacos
CN109966557A (zh) * 2018-12-05 2019-07-05 博志生物科技有限公司 局部缓释Abaloparatide或相关多肽的GelMA水凝胶的制备方法及应用
EP4302773B1 (en) * 2019-09-30 2024-11-06 Tolmar International Limited Liquid polymer compositions and systems for extended delivery of peptides as active pharmaceutical ingredients
CN110946826B (zh) * 2019-12-12 2022-02-22 烟台大学 一种利奥西呱口服制剂及其制备方法
EP4221688A1 (en) 2020-09-30 2023-08-09 Tolmar International Limited Biodegradable polymer and solvent compositions and systems for extended storage and delivery of active pharmaceutical ingredients
KR20240079177A (ko) * 2022-11-28 2024-06-04 동국제약 주식회사 인-시튜 임플란트를 형성할 수 있는 서방형 약학 조성물 및 이의 제조방법
TW202440148A (zh) * 2022-12-23 2024-10-16 大陸商長春金賽藥業有限責任公司 GnRH拮抗劑可注射組合物及其製備方法和用途
CN120603576A (zh) * 2023-02-10 2025-09-05 托尔玛国际有限公司 地加瑞克有机溶剂制剂
EP4661840A2 (en) * 2023-02-10 2025-12-17 Tolmar International Limited Degarelix polymeric formulations
CN119074641A (zh) * 2024-09-02 2024-12-06 万邦德制药集团有限公司 一种含布雷默浪丹药物组合物、制剂及其制备方法和应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US6197320B1 (en) * 1994-03-11 2001-03-06 Shalaby W. Shalaby Absorbable E-caprolactone polymers and medical devices
US5668288A (en) * 1996-04-16 1997-09-16 Depuy Orthopaedics, Inc. Polyester ionomers for implant fabrication
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6201072B1 (en) 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US8470359B2 (en) 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
WO2002038185A2 (en) 2000-11-13 2002-05-16 Atrix Laboratories, Inc. Injectable sustained release delivery system with loperamide
EP1334990A1 (en) 2002-02-06 2003-08-13 Polyganics B.V. DL-Lactide-epsilon-caprolactone copolymers
JP5229768B2 (ja) 2003-06-26 2013-07-03 シヴィダ・ユーエス・インコーポレイテッド In−Situゲル化薬物輸送システム
AU2005316545A1 (en) * 2004-12-15 2006-06-22 Qlt Usa, Inc. Sustained delivery formulations of octreotide compounds
CA2604943C (en) 2005-04-15 2013-09-17 Clarus Therapeutics, Inc. Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
US20080247987A1 (en) 2005-08-04 2008-10-09 Angiotech International Ag Block Copolymer Compositions and Uses Thereof
US20070299043A1 (en) 2005-10-03 2007-12-27 Hunter William L Anti-scarring drug combinations and use thereof
MX2008009125A (es) * 2006-01-18 2008-10-23 Qps Llc Composiciones farmaceuticas con estabilidad mejorada.
US7740877B2 (en) 2006-04-07 2010-06-22 University Of Utah Research Foundation Aliphatically modified biodegradable block copolymers as thermogelling polymers
CL2008003305A1 (es) * 2007-11-06 2009-06-05 M/S Panacea Biotec Ltd Composicion inyectable que comprende un agente activo seleccionado de un grupo definido; al menos un polimero bioerosionable, al menos un solvente no toxico y opcionalmente uno o mas excipientes; proceso de preparacion; uso para tratar enfermedades mentales o cancer.
US20090181068A1 (en) * 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
US8946277B2 (en) 2008-04-18 2015-02-03 Warsaw Orthopedic, Inc. Clonidine formulations in a biodegradable polymer carrier
BRPI0917975A2 (pt) 2008-08-12 2015-11-17 Novartis Ag formulação de depósito de formação local injetável, processo para a preparação da referida formulação, composição farmacêutica, seringa pré-carregada, e uso de peg500 dme
US8541360B2 (en) 2008-11-19 2013-09-24 Ben Venue Laboratories, Inc. Parenteral formulations comprising sugar-based esters and ethers
CA2749997A1 (en) * 2009-01-23 2010-07-29 Surmodics Pharmaceuticals, Inc. Polymer mixtures comprising polymers having different non-repeating units and methods for making and using same
SG175309A1 (en) 2009-04-24 2011-11-28 Iceutica Pty Ltd Production of encapsulated nanoparticles at high volume fractions
GB2481018B (en) * 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
HUE033386T2 (en) 2010-07-09 2017-11-28 Innocore Tech B V Release of Biodegradable Phase Separated Segmented Multiblock Copolymers and Biologically Active Polypeptides
KR20130100345A (ko) * 2010-11-04 2013-09-10 신닛테츠 수미킨 가가쿠 가부시키가이샤 하드코트층 부착 폴리카보네이트
JP2013543898A (ja) 2010-11-24 2013-12-09 デュレクト コーポレイション 生体分解性薬物送達組成物
US20140309202A1 (en) 2010-11-30 2014-10-16 Lipocine Inc. High-strength testosterone undecanoate compositions
US9901554B2 (en) 2011-03-31 2018-02-27 Ingell Technologies Holding B.V. Biodegradable compositions suitable for controlled release
HUE047737T2 (hu) * 2011-06-10 2020-05-28 Ramscor Inc Nyújtott hatóanyag-felszabadítású készítmények fehérjék szembe történõ bejuttatásához, és eljárás ezek elõállítására
CA2852386C (en) * 2011-10-17 2019-05-21 Poly-Med, Inc. Absorbable in situ gel-forming system, method of making and use thereof
EP3137532B1 (en) 2014-05-01 2021-05-26 Ingell Technologies Holding B.V. Liquid triblock copolymer
KR101686986B1 (ko) 2014-07-28 2016-12-16 에스케이케미칼주식회사 류프로라이드를 포함하는 속효성과 지속성을 동시에 갖는 약제학적 조성물
US10786515B2 (en) * 2015-08-03 2020-09-29 Tolmar International Limited Liquid polymer delivery system for extended administration of drugs
US11752099B2 (en) 2017-03-27 2023-09-12 W. L. Gore & Associates, Inc. Injectable and biodegradable polymer formulations for controlled release of bioactive agents

Also Published As

Publication number Publication date
BR112018002414A2 (pt) 2018-09-18
CN107920988A (zh) 2018-04-17
US11779589B2 (en) 2023-10-10
MX2018001499A (es) 2018-08-01
JP2018522906A (ja) 2018-08-16
JP6949820B2 (ja) 2021-10-13
HK1255638A1 (en) 2019-08-23
AU2016302252B2 (en) 2022-01-20
AU2016302252A1 (en) 2018-02-22
WO2017024027A1 (en) 2017-02-09
NZ739674A (en) 2024-10-25
US20240066039A1 (en) 2024-02-29
IL257221A (en) 2018-03-29
EP3331495B1 (en) 2020-11-04
MX378264B (es) 2025-03-10
KR102696721B1 (ko) 2024-08-19
EA036951B1 (ru) 2021-01-19
EA201890436A1 (ru) 2018-09-28
CA2994704A1 (en) 2017-02-09
DK3331495T3 (da) 2020-12-14
ES2836805T3 (es) 2021-06-28
BR112018002414B1 (pt) 2023-11-21
HUE052832T2 (hu) 2021-05-28
ZA201800591B (en) 2021-07-28
ES2975519T3 (es) 2024-07-08
US20210060036A1 (en) 2021-03-04
US12447158B2 (en) 2025-10-21
IL257221B (en) 2022-01-01
KR20180030413A (ko) 2018-03-22
US10786515B2 (en) 2020-09-29
TW201717960A (zh) 2017-06-01
TWI718168B (zh) 2021-02-11
EP3804698B1 (en) 2024-01-31
EP3331495A1 (en) 2018-06-13
CN107920988B (zh) 2021-08-17
PT3331495T (pt) 2020-12-07
US20180214459A1 (en) 2018-08-02
EP3804698A1 (en) 2021-04-14

Similar Documents

Publication Publication Date Title
HRP20201991T1 (hr) Sustav za isporuku tekućeg polimera za produženu administraciju lijekova
JP2018522906A5 (https=)
RU2005117164A (ru) Композиции пролонгированного действия с контролируемым высвобождением
CA2714757A1 (en) Low viscosity liquid polymeric delivery system
CN103491946B (zh) 可生物降解的药物释放组合物
RS66643B1 (sr) Farmaceutska kompozicija
JP2006508127A5 (https=)
CN104582733A (zh) 用于疏水性组合物的可生物降解的药物释放系统
HK1220628A1 (zh) 包含高粘度液体载体的可注射控制释放组合物
KR970702029A (ko) 액체 전달 조성물(Liquid delivery compositions)
ES2340693T3 (es) Composiciones farmaceuticas que comprenden polietilenglicol con un peso molecular menor de 600 daltons.
JP2013533230A5 (https=)
EP2477617A1 (en) Free-standing biodegradable patch
WO2011112996A3 (en) Injectable drug delivery system
US20130157951A1 (en) Pharmaceutical Composition Containing Goserelin for In-Situ Implant
Schoenhammer et al. Injectable in situ forming depot systems: PEG-DAE as novel solvent for improved PLGA storage stability
HRP20250396T1 (hr) Depo sustavi koji sadrže glatiramer acetat
Dzikowski et al. Antibiotic incorporation in jet-sprayed nanofibrillar biodegradable scaffolds for wound healing
RU2320321C2 (ru) Композиции депо кратковременного действия
RS65067B1 (sr) Farmaceutska kompozicija
Liu et al. Effect of polymer type on the dynamics of phase inversion and drug release in injectable in situ gelling systems
FI4302773T3 (fi) Nestemäiset polymeerikoostumukset ja järjestelmät peptidien pitkäaikaiseen annosteluun vaikuttavina farmaseuttisina aineina
Mahadlek et al. Clotrimazole-loaded fatty acid-based in situ forming film oral spray
US20230355511A1 (en) Biodegradable polymer and solvent compositions and systems for extended storage and delivery of active pharmaceutical ingredients
US20170354764A1 (en) Coated balloon catheter and composition for coating said balloon catheter